196 209

Cited 3 times in

Inhibitor of DNA binding 2 is a novel therapeutic target for stemness of head and neck squamous cell carcinoma

DC FieldValueLanguage
dc.contributor.author임재열-
dc.date.accessioned2018-12-14T16:41:45Z-
dc.date.available2018-12-14T16:41:45Z-
dc.date.issued2017-
dc.identifier.issn0007-0920-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/166159-
dc.description.abstractBACKGROUND: Head and neck squamous cell carcinomas (HNSCCs) are highly lethal epithelial tumours containing self-renewal cancer stem cells (CSCs). CSCs in HNSCCs are strongly associated with tumour initiation, invasion, and chemoradiation resistance. However, the important factors regulating stemness in HNSCCs remain unclear. Here, we investigated the molecular roles and clinical significance of inhibitor of DNA binding 2 (Id2) protein to determine if it constitutes a novel therapeutic target for ablating HNSCC cells with stemness. METHODS: We performed in vitro and in vivo studies of Id2 function and its effects on stemness using HNSCC cells. We also examined whether Id2 expression could be used as a prognostic indicator through immunohistochemical staining of 119 human HNSCC tumours. RESULTS: Expression of Id2 was higher in HNSCC cells with stemness compared with differentiated HNSCC cells. Overexpression of Id2 increased proliferation, self-renewal, and expression of the putative stemness marker CD44 in HNSCC cells in vitro and in vivo. In contrast, silencing of Id2 using short hairpin RNA attenuated the stemness phenotype of HNSCC cells by reducing self-renewal, CD44 expression, cisplatin chemoresistance, and xenograft tumourigenicity. Most importantly, increased expression of Id2 was closely associated with poorer post-treatment survival rates in HNSCC patients. CONCLUSIONS: Inhibitor of DNA binding2 represents a novel and promising therapeutic target for treating and improving the clinical outcomes for patients with HNSCC.-
dc.description.statementOfResponsibilityopen-
dc.formatapplication/pdf-
dc.languageEnglish-
dc.publisherNature Publishing Group on behalf of Cancer Research UK-
dc.relation.isPartOfBRITISH JOURNAL OF CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAnimals-
dc.subject.MESHAntineoplastic Agents/pharmacology-
dc.subject.MESHCarcinoma, Squamous Cell/drug therapy-
dc.subject.MESHCarcinoma, Squamous Cell/genetics-
dc.subject.MESHCarcinoma, Squamous Cell/metabolism*-
dc.subject.MESHCell Line, Tumor-
dc.subject.MESHCell Proliferation-
dc.subject.MESHCell Self Renewal/genetics-
dc.subject.MESHCell Survival/drug effects-
dc.subject.MESHCisplatin/pharmacology-
dc.subject.MESHDrug Resistance, Neoplasm/genetics-
dc.subject.MESHFemale-
dc.subject.MESHGene Expression-
dc.subject.MESHGene Silencing-
dc.subject.MESHHead and Neck Neoplasms/drug therapy-
dc.subject.MESHHead and Neck Neoplasms/genetics-
dc.subject.MESHHead and Neck Neoplasms/metabolism*-
dc.subject.MESHHumans-
dc.subject.MESHHyaluronan Receptors/metabolism-
dc.subject.MESHInhibitor of Differentiation Protein 2/genetics*-
dc.subject.MESHInhibitor of Differentiation Protein 2/metabolism*-
dc.subject.MESHMice-
dc.subject.MESHMice, Inbred BALB C-
dc.subject.MESHMice, Nude-
dc.subject.MESHNeoplasm Transplantation/pathology-
dc.subject.MESHNeoplastic Stem Cells/metabolism*-
dc.subject.MESHPhenotype-
dc.subject.MESHSpheroids, Cellular-
dc.subject.MESHSurvival Rate-
dc.titleInhibitor of DNA binding 2 is a novel therapeutic target for stemness of head and neck squamous cell carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Otorhinolaryngology (이비인후과학교실)-
dc.contributor.googleauthorWoo Jin Bae-
dc.contributor.googleauthorBon Seok Koo-
dc.contributor.googleauthorSang Hyuk Lee-
dc.contributor.googleauthorJin Man Kim-
dc.contributor.googleauthorYoung Soo Rho-
dc.contributor.googleauthorJae Yol Lim-
dc.contributor.googleauthorJung Hwa Moon-
dc.contributor.googleauthorJae Hoon Cho-
dc.contributor.googleauthorYoung Chang Lim-
dc.identifier.doi10.1038/bjc.2017.373-
dc.contributor.localIdA03396-
dc.relation.journalcodeJ00406-
dc.identifier.eissn1532-1827-
dc.identifier.pmid29096401-
dc.contributor.alternativeNameLim, Jae Yol-
dc.contributor.affiliatedAuthor임재열-
dc.citation.volume117-
dc.citation.number12-
dc.citation.startPage1810-
dc.citation.endPage1818-
dc.identifier.bibliographicCitationBRITISH JOURNAL OF CANCER, Vol.117(12) : 1810-1818, 2017-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Otorhinolaryngology (이비인후과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.